Table 5.
rhTSH-aided RAI therapy | THW-aided RAI therapy | p-Value | |
---|---|---|---|
Mean first dose activity (mCi) | 222.4±120.8 | 203.5±61.5 | 0.444 |
Mean TSH at the time of the first dose application (mIU/mL) | 42.3±44.9 | 65.9±40.2 | 0.126 |
D-Rx-aided treatment | 80% | 46.3% | 0.024a |
Number of repeated dosages | I dose: 80% | I dose: 46.3% | 0.188 |
II doses: 20% | II doses: 34.1% | ||
III doses: 0% | III doses: 9.8% | ||
IV doses: 0% | IV doses: 9.8% | ||
Mean total cumulative dose (mCi) | 256±136.7 | 414.7±257 | 0.027a |
Mean urine iodine (μg/L) | 117.7±54.8 | 86.7±72.2 | 0.279 |
Additional surgical treatment of metastatic lesions | 13.3% | 31.7% | 0.150 |
Additional radiotherapy treatment | 33.3% | 22% | 0.294 |
Treatment with zolendronic acid | 33.3% | 14.6% | 0.121 |
Total duration of follow-up (months) | 33.5±24.2 | 86.2±224.7 | 0.372 |
Duration of follow-up after the last dose of 131I (months) | 25.2±24.9 | 32.5±27.3 | 0.368 |
Statistically significant difference.
RAI, radioiodine.